Skip to content

Study · Not a test of the peptide alone · 2024

2 results

Endogenous defense mechanism-based neuroprotection in large-vessel acute ischemic stroke: A hope for future.

Goel D, Shangari S, Mittal M, Bhat A

Brain circulation1 Jan 2024Cited by 18 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneRandomized controlled trialEfficacy outcome

    In LMCA stroke patients, citicoline, vinpocetine, edaravone and cerebrolysin with standard care improved motor recovery versus standard care alone.

    In plain wordsIn stroke patients, the regimen containing cerebrolysin improved motor recovery compared with standard care alone.

    Outcome
    IncreaseMotor recovery
    Study

    n = 60

    Comparator
    Standard medical care without neuroprotective agents
    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    The intervention group showed significant and early improvements in motor as well as cognitive recovery.
    2 context sentences
    Summary · context
    Sixty patients of LMCA stroke were enrolled and randomized within 72 h into two groups of 30 patients each.
    Summary · context
    The control group received standard medical care without any neuroprotective agents while the intervention group received standard medical care combined with oral citicoline with vinpocetine for 3 months with initial 1 week intravenous and edaravone and cerebrolysin injection, started within 72 h of onset of stroke.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 02HumanNot a test of Cerebrolysin aloneRandomized controlled trialEfficacy outcome

    In LMCA stroke patients, citicoline, vinpocetine, edaravone and cerebrolysin with standard care improved cognitive recovery versus standard care alone.

    In plain wordsIn stroke patients, the regimen containing cerebrolysin improved cognitive recovery compared with standard care alone.

    Outcome
    IncreaseCognitive recovery
    Study

    n = 60

    Comparator
    Standard medical care without neuroprotective agents
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    The intervention group showed significant and early improvements in motor as well as cognitive recovery.
    2 context sentences
    Summary · context
    Sixty patients of LMCA stroke were enrolled and randomized within 72 h into two groups of 30 patients each.
    Summary · context
    The control group received standard medical care without any neuroprotective agents while the intervention group received standard medical care combined with oral citicoline with vinpocetine for 3 months with initial 1 week intravenous and edaravone and cerebrolysin injection, started within 72 h of onset of stroke.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.